美洛西林钠与头孢哌酮舒巴坦治疗早发性脑卒中相关性肺炎的疗效及安全性比较

摘要

Objective To observe the safety and efficacy between mezlocillin sodium and cefoperazone sulbactam in earlyonset stroke-associated pneumonia patients(EOP).Methods Eighty cases with EOP from January 2010 to January 2015 in our hospital were randomly divided into observation group and control group.Patients in the observation group received mezlocillin sodium,the control group received cefoperazone sulbactam.Then the clinical curative effect and safety between two groups were comparatively analyzed.Results In terms of total effective rate,the significant efficiency rate and the bacterial clearance rate,no significant differences were found between the observation group and the control group(P＞0.05).After treatment,the observation group had significantly lower detection rate of Acinetobacter than the control group,while as for laboratory indexes such as blood cell count,procalcitonin,C-reactive protein,the observation group was obviously prior to the control group(P＜ 0.05).Conclusion Not only mezlocillin sodium but also cefoperazone sulbactam has a good clinical curative effect and bacterial clearance rate in the treatment of EOP.Mezlocillin sodium takes an advantage over cefoperazone sulbactam concerning improving the inflammatory response and has lower detection rate of multiple-drug resistant bacteria,thus which has better safety in clinical application.%目的 观察美洛西林钠与头孢哌酮舒巴坦治疗早发性脑卒中相关性肺炎(EOP)的临床疗效及安全性.方法 选取2010-01-2015-01收治的EOP患者80例,随机分为观察组与对照组,观察组使用美洛西林钠治疗,对照组使用头胞哌酮舒巴坦治疗,对比观察2组临床疗效及安全性.结果 2组总有效率、显效率及细菌清除率差异无统计学意义(P＞0.05);观察组治疗后鲍曼不动杆菌检出率明显低于对照组,白细胞计数、降钙素原、C反应蛋白等实验室指标明显优于对照组,差异均具有统计学意义(P＜0.05).结果 美洛西林钠与头胞哌酮舒巴坦对EOP均具有良好的临床疗效及理想的细菌清除率,美洛西林钠在改善炎症反应方面更为理想,且其多重耐药菌的检出明显较低,临床应用更具有安全性.